Table 1.
Patient demographics and baseline characteristics across all treatment groups.
| Characteristic | Study INCB 54329-101 (n = 69) | Study INCB 57643-101 (n = 134) |
|---|---|---|
| Median (range) age (y) | 63 (18–87) | 66 (19–84) |
| Women, n (%) | 36 (52) | 67 (50) |
| Race, n (%) | ||
| White/Caucasian | 65 (94) | 109 (81) |
| Asian | 4 (6) | 0 |
| Black/African American | 0 | 16 (12) |
| American-Indian/Alaska Native | 0 | 1 (1) |
| Native Hawaiian/Pacific Islander | 0 | 1 (1) |
| Other | 0 | 6 (5) |
| Missing | 0 | 1 (1) |
| ECOG performance status, n (%) | ||
| 0 | 22 (32) | 35 (26) |
| 1 | 47 (68) | 94 (70) |
| ≥2 | 0 | 4 (3) |
| Missing | 0 | 1 (1) |
| Number of prior systemic anticancer therapiesa | ||
| 0 | 0 | 2 (2)b |
| 1 | 5 (7) | 20 (15) |
| 2 | 12 (17) | 19 (14) |
| ≥3 | 52 (75) | 93 (69) |
| Most common tumor typec n (%) | ||
| Prostate cancer | 9 (13) | 15 (11) |
| Colorectal cancer | 8 (12) | 9 (7) |
| Breast cancer | 6 (9) | 18 (13) |
| Ovarian cancer | 5 (7) | 16 (12) |
| Lymphomad | 4 (6) | 20 (15) |
| Acute myeloid leukemia | 3 | 12 (9) |
| Pancreatic cancer | 2 | 7 (5) |
| Glioblastoma | 0 (0) | 7 (5) |
| Myelodysplastic syndrome | 1 (1) | 5 (4) |
| Other | 31 (23) | 25 (19) |
a
Includes all treatments, potentially neoadjuvant, adjuvant, induction/consolidation, local relapse, or in metastatic setting; may also include multiple cycles for the same treatment (may or may not be considered the same line treatment).
b
Patients had no known SOC therapies available.
c
Occurring in ≥5 patients in either study.
d
Lymphoma subtypes according to disease history assessed at screening (study INCB 54329-101: DLBCL (n = 2), lymphoblastic lymphoma (n = 1); lymphoma subtype not reported (n = 1); study INCB 57643-101: DLBCL (n = 11), FL (n = 8), and splenic marginal zone lymphoma (n = 1).